GE Healthcare partners up with Minerva on precision medicine

A deal has been struck under the banner of accelerating targeted radionuclide therapy and precision medicine between GE Healthcare and Minerva Imaging.

Carsten Nielsen, CEO and co-founder of Minerva Imaging | Photo: Minerva Imaging / PR

US-based GE Healthcare and Danish Minerva Imaging have entered into a strategic partnership "to accelerate precision medicine and targeted radionuclide therapy," a press release announces.

Radionuclide therapy, which is a type of precision medicine, entails a radioactive substance being administered into the bloodstream to target and irradiate cancer cells. The therapy is designed to reduce the potential side effects compared to traditional cancer treatments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs